Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis | MicrobiomeTrials← Back to trialsNCT06465810
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
RecruitingOBSERVATIONAL
Trial Details
Start: 2024-06-25Est. Completion: 2031-12-29
Enrollment target: 1,850 participants Locations- Research Site, La Jolla, California, United States
- Research Site, Los Angeles, California, United States
- Research Site, San Francisco, California, United States
- Research Site, San Francisco, California, United States
- Research Site, New Haven, Connecticut, United States
- Research Site, Washington D.C., District of Columbia, United States
- Research Site, Chicago, Illinois, United States
- Research Site, Indianapolis, Indiana, United States
- Research Site, Boston, Massachusetts, United States
- Research Site, Boston, Massachusetts, United States
- Research Site, Boston, Massachusetts, United States
- Research Site, Rochester, Minnesota, United States
- Research Site, Kansas City, Missouri, United States
- Research Site, St Louis, Missouri, United States
- Research Site, New Brunswick, New Jersey, United States
- Research Site, Manhasset, New York, United States
- Research Site, New York, New York, United States
- Research Site, New York, New York, United States
Other microbiome trials you might be interested in
Symptomatic Transthyretin Amyloid Cardiomyopathy
This prospective study is designed to evaluate the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), …
Bunkyō City, JapanCompleted Nov 8, 2023
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safe…
La Jolla, United StatesEst. completion Feb 23, 2029
Research Site, Durham, North Carolina, United StatesResearch Site, Portland, Oregon, United StatesResearch Site, Danville, Pennsylvania, United StatesResearch Site, Philadelphia, Pennsylvania, United StatesResearch Site, Philadelphia, Pennsylvania, United StatesResearch Site, Greenville, South Carolina, United StatesResearch Site, Germantown, Tennessee, United StatesResearch Site, Nashville, Tennessee, United StatesResearch Site, Dallas, Texas, United StatesResearch Site, Richmond, Virginia, United StatesResearch Site, Seattle, Washington, United StatesResearch Site, Milwaukee, Wisconsin, United StatesResearch Site, Vancouver, British Columbia, CanadaResearch Site, Vancouver, British Columbia, CanadaResearch Site, Halifax, Nova Scotia, CanadaResearch Site, London, Ontario, CanadaResearch Site, Toronto, Ontario, CanadaResearch Site, Rimouski, Quebec, CanadaResearch Site, Beijing, Beijing Municipality, ChinaResearch Site, Beijing, Beijing Municipality, ChinaResearch Site, Beijing, Beijing Municipality, ChinaResearch Site, Fuzhou, Fujian, ChinaResearch Site, Guangzhou, Guangdong, ChinaResearch Site, Guangzhou, Guangdong, ChinaResearch Site, Changsha, Hunan, ChinaResearch Site, Nanchang, Jiangxi, ChinaResearch Site, Shanghai, Shanghai Municipality, ChinaResearch Site, Hebei Sheng, Shijiazhuang, ChinaResearch Site, Shaanxi, Xi'An, ChinaResearch Site, Würzburg, Bavaria, GermanyResearch Site, Frankfurt am Main, Hesse, GermanyResearch Site, Hanover, Lower Saxony, GermanyResearch Site, Aachen, North Rhine-Westphalia, GermanyResearch Site, Cologne, North Rhine-Westphalia, GermanyResearch Site, Mainz, Rhineland-Palatinate, GermanyResearch Site, Homburg, Saarland, GermanyResearch Site, Berlin, GermanyResearch Site, Yamagata, JapanResearch Site, Huelva, Andalusia, SpainResearch Site, Cataluna, Barcelona, SpainResearch Site, Bilbao, Basque Country, SpainResearch Site, Las Palmas de Gran Canaria, Canary Islands, SpainResearch Site, Salamanca, Castille and León, SpainResearch Site, Barcelona, Catalu A, SpainResearch Site, Majadahonda, Madrid, SpainResearch Site, Islas Baleares, Palma de Mallorca, SpainResearch Site, Birmingham, West Midlands, United KingdomResearch Site, Glasgow, United KingdomResearch Site, London, United KingdomPhase 3
Recruiting
Transthyretin Amyloid Cardiomyopathy
The purpose of this study is to investigate the effect of eplontersen compared to placebo on the reduction of serum TTR …
Beijing, ChinaEst. completion May 13, 2026